Biogen Inc. (BIIB)
BIIBNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$253.24
-1.64 (-0.64%) today
Regular session, Nov 10, 2:10 PM ET
- Market cap
- $37.42bn
- P/E
- 21.5
- EPS, last 4 quarters
- $11.78
- Dividend yield
- –
- Day range
- $250.44 to $254.70
- 52-week range
- $153.77 to $261.00
- Average volume
- 1.15m
- Previous close
- $254.87
Analysts
26 coveringBuy18 buy, 7 hold, 1 sell
Targets a year out average $268.31, +6.0% from here
Earnings
next estimate $2.85Next report
Dec 2025
+23.6%
Mar 2026
+21.0%
Jun 2026
+18.4%
Sep 2026
+27.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $2.28bn | $2.48bn | $2.74bn | $2.80bn |
| Gross profit | $1.78bn | $1.82bn | $1.96bn | $2.06bn |
| Operating income | $98.40m | $397.40m | $150.90m | $128.40m |
| Net income | -$48.90m | $319.50m | $97.50m | -$20.60m |
Last four quarters: revenue $10.30bn, margin 3.4%, free cash flow $2.07bn
News
8 latest- Biogen And UCB Report Post-Hoc Phase 3 Data For DPZ Indicating Lower Disease Activity In Lupus RTTNews · 1 day ago
- Kenvue Now #267 Largest Company, Surpassing Biogen BNK Invest · 4 days ago
- DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?Zacks · 5 days ago
- State Street SPDR S&P Biotech ETF Experiences Big OutflowBNK Invest · Nov 2, 2026
- Argus Research Upgrades Biogen to Buy from HoldFintel · Oct 30, 2026
- BioArctic Royalty Income Rises 74% As Leqembi Sales Reach JPY 32.2 Bln RTTNews · Oct 29, 2026
- Biogen Q3 Earnings Call HighlightsMarketBeat · Oct 28, 2026
- Biogen (BIIB) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 28, 2026
The company
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- biogen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.